scholarly journals Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies

2021 ◽  
Vol 21 (7) ◽  
Author(s):  
Tyler Ellis Smith ◽  
Ilya Kister
Keyword(s):  
Multiple Sclerosis ◽  
Mitigation Strategies ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

scholarly journals Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies

2018 ◽  
Vol 4 (2) ◽  
pp. 205521731878334 ◽  
Author(s):  
Francisco Coret ◽  
Francisco C Pérez-Miralles ◽  
Francisco Gascón ◽  
Carmen Alcalá ◽  
Arantxa Navarré ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Progressive Multiple Sclerosis ◽  
Secondary Progressive Multiple Sclerosis ◽  
Secondary Progressive ◽  
Disease Modifying Therapies ◽  
Relapsing Remitting ◽  
Disease Modifying ◽  
Remitting Multiple Sclerosis ◽  
Multiple Sclerosis Patients ◽  
Relapsing Remitting Multiple Sclerosis

Background Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing–remitting multiple sclerosis patients. Methods Our study included 204 patients treated for relapsing–remitting multiple sclerosis between 1995 and 2002, prospectively followed to date. Kaplan–Meier analysis was applied to estimate the time until secondary progressive multiple sclerosis conversion, and multivariate survival analysis with a Cox regression model was used to analyse prognostic factors. Results Relapsing–remitting multiple sclerosis patients were continuously treated for 13 years (SD 4.5); 36.3% converted to secondary progressive multiple sclerosis at a mean age of 42.6 years (SD 10.6), a mean time of 8.2 years (SD 5.2) and an estimated mean time of 17.2 years (range 17.1–18.1). A multifocal relapse, age older than 34 years at disease onset and treatment failure independently predicted conversion to secondary progressive multiple sclerosis but did not influence the time to reach an Expanded Disability Status Scale of 6.0. Conclusions The favourable influence of disease-modifying therapies on long-term disability in relapsing–remitting multiple sclerosis is well established. However, the time to progression onset and the subsequent clinical course in treated patients seem similar to those previously reported in natural history studies. More studies are needed to clarify the effect of disease-modifying therapies once the progressive phase has been reached.

Assessment and management of infectious risk in multiple sclerosis patients treated with disease-modifying therapies

2021 ◽  
Vol 429 ◽  
pp. 117753
Author(s):  
Maria Antonella Zingaropoli ◽  
Patrizia Pasculli ◽  
Marco Iannetta ◽  
Valentina Perri ◽  
Matteo Tartaglia ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Infectious Risk ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

Pregnancy Outcome in Multiple Sclerosis Patients Exposed to Disease Modifying Therapies

2020 ◽  
Vol 37 ◽  
pp. 101581
Author(s):  
Samar Farouk Ahmed ◽  
Manal L Almutairi ◽  
Jasem Al-Hashel ◽  
Raed Alroughani
Keyword(s):  
Multiple Sclerosis ◽  
Pregnancy Outcome ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients

Natalizumab (Tysabri) in multiple sclerosis patients

2008 ◽  
Vol 9 (2) ◽  
pp. 109-114
Author(s):  
Viola Sacchi
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Symptom Relief ◽  
Interferon Β ◽  
Disease Modifying Therapies ◽  
Mental Symptoms ◽  
The Central Nervous System ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients ◽  
Immunomodulating Drugs

Multiple sclerosis (MS) is an autoimmune disease where dysregulated immune system elements (i.e. leucocytes) react against different components of the central nervous system (CNS), in particular myelin structures, causing several physical and mental symptoms,often progressing to total disability. While some treatments for MS provide only symptom relief, the most commonly drugs administered for altering the course of the disease are DMTs (disease-modifying therapies); nevertheless for more than ten years the only DMTs available were interferon β, glatiramer acetate (two immunomodulating drugs) and mitoxantrone (an immunosuppressant).

Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk

2016 ◽  
Vol 370 ◽  
pp. 13-17 ◽  
Author(s):  
Deeya Gaindh ◽  
Katelyn S. Kavak ◽  
Barbara Teter ◽  
Caila B. Vaughn ◽  
Diane Cookfair ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cancer Risk ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients ◽  
Risk Of Cancer

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

2016 ◽  
Vol 22 (6) ◽  
pp. 801-809 ◽  
Author(s):  
Sandra Thiel ◽  
Annette Langer-Gould ◽  
Milena Rockhoff ◽  
Aiden Haghikia ◽  
Annette Queisser-Wahrendorf ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Birth Weight ◽  
Preterm Birth ◽  
Pregnancy Outcomes ◽  
Interferon Beta ◽  
First Trimester ◽  
Disease Modifying Therapies ◽  
Disease Modifying ◽  
Multiple Sclerosis Patients ◽  
Pregnancy Registry

Background: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients. Methods: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was obtained. Results: We collected data on 251 pregnancies exposed to interferon-beta and 194 unexposed to disease-modifying therapies. In all, 246 (98.01%) women discontinued interferon-beta treatment during first trimester. No differences regarding mean birth weight (exposed: 3272.28 ± 563.61 g; unexposed: 3267.46 ± 609.81 g), mean birth length (exposed: 50.73 ± 3.30 cm; unexposed: 50.88 ± 3.45 cm), preterm birth ( p = 0.187), spontaneous abortion ( p = 0.304), and congenital anomalies ( p = 0.197) were observed between the two groups. Conclusions: Interferon-beta exposure during early pregnancy does not influence the mean birth weight, risk of preterm birth, or other adverse pregnancy outcomes. Our study provides further reassurance that interferon-beta treatment can be safely continued up until women become pregnant.

Sign in / Sign up

Export Citation Format

Share Document